Adcendo
ID: 7642538Developer of antibody-drug conjugates (ADCs) for cancer treatment.
6
Funding Rounds
$61.8m
Money raised
Recent Funding Rounds
Overview
Developer of antibody-drug conjugates (ADCs) for cancer treatment.
- Website:
- Business model: B2B
- Headquarters: Copenhagen
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| He**** St*** |
|
- | - |
| Ch********* Ni***** |
|
- | |
| La** H. En******* |
|
- | - |
| Ni*** Be****** |
|
- | - |
Funding
Funding series
Funding Series Analysis
The company Adcendo has raised a total of $311.2m in funding over 6 rounds.
Key Insights:
- Adcendo Series B Round, November 2024: $135m
- Adcendo May 2024 Series A Funding Round: $17m
- Adcendo April 2023 Series A Funding Round: $34m
- ADCendo Series A round, April 2021: $61.8m
- Adcendo April 2021 Series A Funding Round: $62m
- Adcendo August 2019 Debt Funding Round: $1.4m
Industries
Adcendo is active in the following industries: